-
Product Insights
NewNet Present Value Model: Ascendis Pharma AS’s TransCon CNP
Empower your strategies with our Net Present Value Model: Ascendis Pharma AS's TransCon CNP report and make more profitable business decisions.Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Trappsol Cyclo in Niemann-Pick Disease Type C
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Trappsol Cyclo in Niemann-Pick Disease Type C report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Trappsol Cyclo in Niemann-Pick Disease Type C Drug Details:...
-
Product Insights
Net Present Value Model: Trappsol Cyclo
Overview Evaluating the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the market currently and in the future, knowledge of cash inflows and outflows and the potential success rates for each stage of drug development. GlobalData has done all of this work for you, leveraging its gold standard Drugs Intelligence database to create high-value NPV models for purchase on a drug-by-drug basis. Drug Operating Profit Model Trappsol Cyclo Drug Details Trappsol Cyclo...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Trappsol Cyclo
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry Trappsol Cyclo Drug Details Trappsol Cyclo is under development for the treatment of Niemann...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – celecoxib
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry celecoxib Drug Details Celecoxib is under development for the treatment of macular edema and...
-
Product Insights
Net Present Value Model: Zynrelef
Overview Evaluating the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the market currently and in the future, knowledge of cash inflows and outflows and the potential success rates for each stage of drug development. GlobalData has done all of this work for you, leveraging its gold standard Drugs Intelligence database to create high-value NPV models for purchase on a drug-by-drug basis. Drug Operating Profit Model Zynrelef Drug Details Bupivacaine and Meloxicam...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – methyl salicylate
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry methyl salicylate Drug Details Methyl salicylate (SPR-300) is under development for the treatment of...